环硅酸锆钠对维持性血液透析患者血钾水平、不良反应、临床疗效的影响  

Effect of Sodium Zirconium Cyclosilicate on Blood Potassium Level,Adverse Reactions and Clinical Efficacy in Maintenance Hemodialysis Patients

作　　者：徐正群 冯彬 许阳 XU Zhengqun;FENG Bin;XU Yang(Renal Department,Yangzhou Second People's Hospital,Yangzhou 225007,China;不详)

机构地区：[1]扬州市第二人民医院肾内科,江苏扬州225007

出　　处：《中国医学创新》2024年第26期119-123,共5页Medical Innovation of China

摘　　要：目的:研究环硅酸锆钠对维持性血液透析(MHD)患者血钾水平、不良反应、临床疗效的影响。方法:选取2021年10月—2023年10月扬州市第二人民医院收治的100例MHD患者。采用随机数字表法将患者分为对照组及观察组,各50例。两组均予常规MHD治疗,对照组采用低钾饮食方案、健康教育和基本降压、纠正贫血及钙、磷代谢异常等措施,观察组在对照组治疗基础上予环硅酸锆钠治疗。比较两组血钾相关指标(血钾、血钙、血钠、血镁、血磷)、不良反应发生率及临床疗效。结果:治疗前后,两组血钙、血钠、血镁及血磷水平比较,差异均无统计学意义(P>0.05);治疗后,观察组血钾水平低于治疗前,且明显低于对照组(P<0.05)。观察组不良反应发生率为4.00%,对照组为2.00%,两组比较,差异无统计学意义(P>0.05)。观察组总有效率为98.00%,对照组为84.00%,观察组高于对照组(P<0.05)。结论:环硅酸锆钠能降低MHD患者血钾水平,不会引起体内电解质紊乱,临床疗效较好,且不良反应发生率较低。Objective:To investigate the effect of Sodium Zirconium Cyclosilicate on blood potassium levels,adverse reactions,and clinical efficacy in maintenance hemodialysis(MHD)patients.Method:A total of 100 MHD patients admitted to Yangzhou Second People's Hospital from October 2021 to October 2023 were selected,and were divided into control group and observation group by random number table method,with 50 cases in each group.Both groups were treated with conventional MHD,while the control group was treated with low potassium diet,health education,basic blood pressure reduction,correction of anemia and abnormal metabolism of calcium and phosphorus.The observation group received Sodium Zirconium Cyclosilicate treatment on the basis of the control group's treatment.Blood potassium related indicators(blood potassium,blood calcium,blood sodium,blood magnesium,blood phosphorus),incidence of adverse reactions and clinical efficacy were compared between two groups.Result:There were no significant differences in blood calcium,blood sodium,blood magnesium,and blood phosphorus levels between the two groups before and after treatment(P>0.05);after treatment,the blood potassium level in the observation group was lower than that before treatment and significantly lower than that in the control group(P<0.05).The incidence of adverse reactions in the observation group was 4.00% and 2.00% in the control group,there was no significant difference between the two groups(P>0.05).The total effective rate of the observation group was 98.00%,while that of the control group was 84.00%,that in observation group was higher than that in the control group(P<0.05).Conclusion:Sodium Zirconate Cyclosilicate can reduce blood potassium levels in MHD patients,without causing electrolyte disorders in the body,it has good clinical efficacy and a low incidence of adverse reactions.

关 键 词：环硅酸锆钠 维持性血液透析 血钾水平 不良反应 

分 类 号：R692.5[医药卫生—泌尿科学]